Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 2/20 | 0.54 |
| ▸ | ARG2 | P78540 | 5/20 | 0.48 |
| ▸ | ARG1 | P05089 | 3/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803840 | 1.00 | DDAH1 (0.55) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL19305284 | 1.00 | DDAH1 (0.55) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL1272384 | 0.94 | GSR (0.57) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL4260017 | 0.94 | GSR (0.57) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL1272453 | 0.94 | GSR (0.57) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL17131071 | 0.92 | GSR (0.55) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL19305283 | 0.92 | GSR (0.55) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL19305282 | 0.92 | GSR (0.55) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL15329383 | 0.92 | GSR (0.55) | DDAH1GSRARG2ARG1GRIK1 | |
| SCHEMBL1272387 | 0.92 | GSR (0.55) | DDAH1GSRARG2ARG1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081244-B1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2025-11-26 | — | — | EP | claimed |
| US-20230270825-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-08-31 | — | — | US | claimed |
| EP-4081244-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC (US) | 2022-11-02 | — | — | EP | claimed |
| CN-115243708-A | Stapled alkene co-agonists of glucagon and GLP-1 receptor | 默沙东有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-3628680-B1 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2021-09-08 | — | — | EP | claimed |
| WO-2021133643-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | WO | claimed |
| EP-3842449-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-30 | — | — | EP | claimed |
| EP-3628680-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2020-04-01 | — | — | EP | claimed |
| US-20190055291-A1 | FUSION RESPIRATORY SYNCYTIAL VIRUS INHIBITORS AND USE THEREOF | HES-SO VALAIS (CH) | 2019-02-21 | — | — | US | claimed |
| EP-3423471-A1 | FUSION RESPIRATORY SYNCYTIAL VIRUS INHIBITORS AND USE THEREOF | Fondation The Ark (CH) | 2019-01-09 | — | — | EP | claimed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | claimed |
| EP-3154561-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191951-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2016123371-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2015191951-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015022283-A1 | YAP-TEAD INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| US-20140357841-A1 | Method for stabilizing polypeptide into alpha helix | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | DDAH1 1846/4885GSR 2238/4885ARG2 1606/4885 |
| US-20230270825-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GIPR, GCGR | DDAH1 3762/4885GSR 1221/4885ARG2 1410/4885 |
| US-20190055291-A1 | FUSION RESPIRATORY SYNCYTIAL VIRUS INHIBITORS AND USE THEREOF | BST2, TMPRSS4, TMPRSS2 | DDAH1 1858/4885GSR 1529/4885ARG2 1157/4885 |
| US-20140357841-A1 | Method for stabilizing polypeptide into alpha helix | PTMA, PTMS, CRYAA | DDAH1 1011/4885GSR 1270/4885ARG2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.